Imaging and Blood Tests to Track Amyotrophic Lateral Sclerosis Over Time
Studies brain and spine scans and blood tests in adults with ALS and healthy people.
Plain-language title generated from the registry record
Registry title: Multicenter ALS Imaging Study
Key facts
- Where
- Evanston, Gainesville, and Minneapolis, United StatesSee the 3 sites
Where in United States
- Northwestern UniversityEvanston, United StatesTaking people
- University of FloridaGainesville, United StatesTaking people
- University of MinnesotaMinneapolis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Minnesota
- Trial code
- NCT06735014
- Record updated
- 31 July 2026
- Original description
This is a multi-site study of ALS participants and healthy controls who will undergo brain and cervical spine MRIs and NfL blood testing at up-to 4 time points over the course of a year. The primary goal is to identify objective biomarkers of disease progression that are biologically relevant, linearly progressive, and sensitive to change.Read full original descriptionShow less
Multicenter Longitudinal Imaging in ALS for Disease Biomarker Development
This is a multi-site study of ALS participants and healthy controls who will undergo brain and cervical spine MRIs and NfL blood testing at up-to 4 time points over the course of a year. The primary goal is to identify objective biomarkers of disease progression that are biologically relevant, linearly progressive, and sensitive to change.
Exclusion: Individuals will be excluded if they have any condition that makes MRI unsafe or if they are unable to comply with instructions; All participants will undergo a neurologic examination at enrollment. Control participants with clinically significant abnormal findings on neurological examination will be excluded from the study.
For participants with ALS:; < 36 months since onset of symptoms; Definite, probable, lab-supported probable, or possible ALS by El Escorial criteria OR definite, probable, or possible ALS per Awaji-Shima criteria OR meets Gold Coast criteria; Forced vital capacity within the last 90 days ≥ 60% of the predicted value; Able to consent for themselves; Able to read and speak English; Clear of any contraindications for MRI.